CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00664677
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:35:59.833894+00:00
Published At: 2016-02-23T00:00:00+00:00
Record Updated At: 2016-02-23
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Leukemias", "Acute Myeloid Leukemia (AML)", "Acute Lymphocytic Leukemia (ALL)", "Adult T Cell Leukemia (ATL)", "Chronic Myeloid Leukemia (CML-BP)", "Chronic Lymphocytic Leukemia (CLL)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-02-23"
protocolSection.identificationModule.nctId: "NCT00664677"
protocolSection.identificationModule.officialTitle: "Phase 1 Study of Terameprocol (EM-1421) a Survivin and Cyclin-Dependent Kinase-1 (Cdc2) Inhibitor, in Patients With Leukemia"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.